Fund Holdings — Versant Venture Management, LLC

Total Portfolio Value
$103.14M
Total Bought
$31.40M
Total Sold
$324.03M
Net Transaction
-$292.63M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q4 2023
▲▼
Q1 2024
▲▼
Change
▲▼
Q4 2023
▲▼
Q1 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Skye Bioscience, Inc.(SKYE)02,007,702+2,007,702031,40030.45%+31,400
Adverum Biotechnologies, Inc.5,068,233506,822-4,561,4113,8157,1666.95%+3,351
CRISPR Therapeutics AG(CRSP)498,558498,558031,21033,98232.95%+2,772
Gritstone Oncology, Inc.3,561,1503,561,15007,2659,1528.87%+1,887
Passage Bio, Inc.(PASG)4,959,7694,959,76905,0096,6966.49%+1,686
Aligos Therapeutics, Inc.2,320,3812,320,38101,5412,2742.20%+733
Repare Therapeutics, Inc.2,646,6572,646,657019,32112,46612.09%-6,855
RayzeBio, Inc.5,158,1610-5,158,161320,6830—-320,683
Page 1 of 1
Versant Venture Management, LLC — 13F Holdings — Q1 2024 | TickerTrail